Get the Stockscreener App
886.63
0.96%
8.39
After Hours:
885.61
-1.02
-0.12%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $886.63, with a volume of 3.07M.
It is up +0.96% in the last 24 hours and down -15.72% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$878.24
Open:
$888.48
24h Volume:
3.07M
Relative Volume:
1.02
Market Cap:
$792.08B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
39.25
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-2.63%
1M Performance:
-15.72%
6M Performance:
+22.04%
1Y Performance:
+7.80%
1-Day Range:
$883.11
$897.43
1-Week Range:
$877.11
$922.15
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
886.63 | 784.58B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
242.49 | 579.15B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
213.12 | 370.38B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
193.88 | 292.21B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.10 | 295.77B | 64.93B | 18.26B | 12.36B | 7.2751 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Video Eli Lilly inks $2.8B AI drug discovery deal - abcnews.com
FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices - Law360
Vital Signs: The biggest spenders of the first quarter - FirstWord Pharma
Stock Market Today, March 30: High Oil Prices Drive Risk-Off Sentiment, Nasdaq Falls 0.7% - The Motley Fool
Mounjaro fat jab maker Eli Lilly calls for NHS price hikes in return for resuming investment in the UK - This is Money
LLY: Guggenheim Adjusts Price Target While Maintaining Buy Ratin - GuruFocus
Eli Lilly's $2.75B Pact Is Latest In AI Drug Discovery Push - Law360
Eli Lilly (NYSE:LLY) Expands Pharmaceutical Reach Amid Strong Market Activity - Kalkine Media
Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing | PharmExec - Pharmaceutical Executive
Mounjaro maker wants NHS drug price rises in return for more investment in UK - The Guardian
Insilico Medicine & Eli Lilly Expand AI Drug Discovery Deal to $2.75BNews and Statistics - IndexBox
Lilly’s AI commitment expands through deal with Insilico - biopharmadive.com
Lilly taps Insilico AI in $2.75B deal to expand pipeline options - BioWorld MedTech
Eli Lilly Deal Is a Bet on AI. What It Means for the Stock. - Barron's
Eli Lilly's CEO Says This Could Be a Game Changer for Its Business - The Motley Fool
Eli Lilly Stock (LLY) Gets a Boost from Plan to Make Drugs Using AI - TipRanks
Eli Lilly and Company (NYSE:LLY) Price Target Lowered to $1,163.00 at Guggenheim - MarketBeat
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership - Investopedia
Eli Lilly teams up with Insilico to accelerate AI-powered drug development - proactiveinvestors.com
Eli Lilly and Company (LLY) Continued to Gain from Its Incretin Portfolio - Yahoo Finance
Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery - Reuters
Guggenheim lowers Eli Lilly stock price target to $1,163 on Q1 estimates - Investing.com
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,163 - 富途牛牛
Eli Lilly’s (LLY) Shares Up Since Jim Cramer Said He Was a Long Term Believer - Insider Monkey
Eli Lilly bets on AI-powered drugs in new deal with Insilico Medicine - Euronews.com
Eli Lilly strikes up to $2.75bn deal with Insilico to accelerate push into AI-developed medicines - InvestmentNews
Eli Lilly and Insilico Medicine forge $2.75bn AI-driven R&D pact - Pharmaceutical Technology
Planning review for $3.5B Eli Lilly plant addresses traffic, environment in Lehigh Valley - lehighvalleylive
Eli Lilly & Co (NYSE:LLY): A Prime Dividend Growth Candidate Backed by Strong Profitability - ChartMill
Eli Lilly Expands Insilico AI Drug Discovery Deal to $2.75 Billion - AIM Media House
Trending tickers: Exxon Mobil, Eli Lilly, Rio Tinto and Boohoo - Yahoo Finance UK
Eli Lilly and Company $LLY Shares Acquired by Exchange Traded Concepts LLC - MarketBeat
Lilly Grows AI Footprint with Up-to-$2.75B Insilico Collaboration - Genetic Engineering and Biotechnology News
Eli Lilly Strikes $2.75bn AI Drug Deal With Insilico in Major Bet on Next-Generation Drug Discovery - Tekedia
Lilly, Insilico ink deal on AI drugs worth up to $2.75 billion - MSN
Eli Lilly & Insilico Medicine Ink $2.75Bn AI Drug Discovery Deal for Next-Gen Treatment - outlookbusiness.com
Eli Lilly is printing money from obesity… and still buying AI for $2.75 billion? - Moomoo
Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports - Reuters
Eli Lilly, InSilico Strike AI Drug Discovery Deal - WSJ
Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg
Prediction: Buying Pfizer Stock Today Could Set You Up for Life - AOL.com
Jefferies Remains a Buy on Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly Partners with Insilico on AI Drug Discovery Worth Up to $2.75 Billion - MLQ.ai
Eli Lilly Secures $2.75 Billion Deal With Insilico Medicine To Bring AI-Developed Drugs To Global Market: Report - Benzinga
Eli Lilly Links to ESPN’s Pat Summitt Reunion Special, Seeking New Ways to Tell Medical Stories - Variety
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus - TechStock²
Lilly, Insilico Ink Deal On AI Drugs Worth Up To $2.75 Billion - NDTV Profit
Eli Lilly Bets $2.75B on AI Drug Discovery in Insilico Deal - The Tech Buzz
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market - CNBC
Insilico Medicine secures US$2.75 bil drug collaboration with Eli Lilly - The Edge Malaysia
InSilico, Lilly ink AI drug discovery deal worth up to $2.75 billion By Investing.com - Investing.com South Africa
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.85%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):